Late-breaking Data: Apremilast Reduces Symptoms, Boosts Quality of Life for Palmoplantar Pustulosis Patients
Apremilast (Otzela, Amgen) can improve symptoms in patients with moderate to severe palmoplantar pustulosis who had an inadequate response to topical therapy, according to a late-breaking Phase 3 study presented at the annual meeting of the American Academy of Dermatology in San Diego, CA. The randomized, placebo-controlled, double-blind study included 176 patients who received apremilast (n=88) […]